RT info:eu-repo/semantics/article
T1 Resting-state gamma activity as a discriminative marker for cognitive subtypes in psychosis
A1 Osorio Iriarte, María Emma
A1 Díez Revuelta, Álvaro
A1 Fernández Linsenbarth, Ines
A1 Arjona Valladares, Antonio
A1 Beño Ruiz De La Sierra, Rosa María
A1 Roig Herrero, Alejandro
A1 Martínez Sánchez, José María
A1 Sobrino Conde, Luis
A1 Molina Rodríguez, Vicente
K1 Electroencephalography
K1 Resting-state EEG
K1 Gamma band
K1 Schizophrenia
K1 Biomarker
K1 3211 Psiquiatría
AB Background and hypothesis: Schizophrenia and other psychotic disorders exhibit significant clinical and cognitiveheterogeneity, challenging diagnosis and treatment. Given indications of widespread cortical hyperactivity anddysregulation of neural oscillations in schizophrenia, investigating resting-state activity is highly relevant. Thisstudy examined resting-state EEG alterations across previously defined cognitive subtypes within the psychosisspectrum.Study design: We analyzed resting-state EEG data from 141 psychosis patients (64 chronic schizophrenia, 40 first-episode schizophrenia, 37 bipolar disorder) and 80 healthy controls. Patients were a priori classified into twodistinct cognitive subgroups: Cluster 1 (severe impairment, n = 47) and Cluster 2 (moderate impairment, n =94).Study results: Both patient clusters exhibited increased spectral power across most frequency bands compared tohealthy controls. Notably, the more severely impaired Cluster 1 showed significantly higher power in thegamma-1 band (30–45 Hz) compared to Cluster 2. Furthermore, in Cluster 1, a significant positive correlationwas found between resting-state gamma-1 power and positive symptom scores.Conclusions: These results support our hypothesis of distinctive basal hyperactivation linked to the cognitiveprofile, suggesting that altered intrinsic brain activity, particularly gamma-1 hyperactivation, may underliecognitive heterogeneity in psychosis. This also suggests that gamma-1 band hyperactivation at rest serves as adistinct neurophysiological marker differentiating both subgroups. Our findings highlight the importance ofsubdivision approaches to identify more homogeneous patient subgroups and emphasize the potential of resting-state gamma activity as a precise biomarker for specific symptom dimensions and personalized treatmentstrategies.
PB Elsevier
SN 0278-5846
YR 2026
FD 2026
LK https://uvadoc.uva.es/handle/10324/83315
UL https://uvadoc.uva.es/handle/10324/83315
LA eng
NO Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2026, vol. 145, p. 111646
NO Producción Científica
DS UVaDOC
RD 04-mar-2026